Authors:Seet RC, Quek AM, Ooi DS, Sengupta S, Koo CY. PMID:PMC8056783 DOI: 10.1016/j.ijid.2021.04.035 Abstract Background: We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19). Methods: An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined [...]

Authors: Rossignol JF, Bardin MC, Oaks JB, Bostick BG, Vora KN. doi: https://doi.org/10.1101/2021.04.19.21255441 Abstract Background There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization. Methods This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment [...]

Authors: Karimi A, Naeini F, Azar VA, Hasanzadeh M PMID: 33940332 DOI: 10.1016/j.phymed.2021.153567 Abstract Background: Sepsis is a life-threatening condition caused by a dysregulated host response to infection. Several studies have indicated that flavonoids exhibit a wide variety of biological actions including free radical scavenging and antioxidant activities. Quercetin, one of the most extensively distributed [...]

Authors: Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C et al. PMID: 33844996 PMCID: PMC8040526 DOI: 10.1016/S2213-2600(21)00160-0 Abstract Background: Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocorticoids [...]

INTRODUCTION: Our aim was to investigate the efficacy of vitamin C, melatonin, and zinc in patients with severe Covid-19.

Authors: Shoaibi A, Fortin S, Weinstein R, Berlin JA PMID: 33982938 DOI: 10.14309/ajg.0000000000001153 Abstract Introduction: Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, [...]

Authors: Aveyard P, Gao M, Lindson N, Young D, Tan PS, Clift AK PMID: 33812494 PMCID: PMC8016404 DOI: 10.1016/S2213-2600(21)00095-3 Abstract Background: Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with COVID-19 was lower than its prevalence in the general population. The aim of this study was [...]

Authors: Wehbe Z, Wehbe M, Iratni R, Pintus G, Zaraket H PMID: 33859652 PMCID: PMC8043070 DOI: 10.3389/fimmu.2021.663586 Abstract As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world. As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19. Several vaccines, including mRNA, vector-based vaccines, [...]

Authors: Hong SK, Kim HJ, Song CS, Choi IS, Lee JB PMID: 22430099 DOI: 10.1016/j.intimp.2012.03.002 Abstract Suppression of interleukin (IL)-6 production has beneficial effects against various inflammatory diseases. Through a rapid screening system, we found that nitazoxanide, or 2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide, which is a well-known antiparasitic agent, suppressed lipopolysaccharide (LPS)-induced production of IL-6 from RAW 264.7 [...]

Authors: Marik PE, DePerrior SE, Ahmad Q, Dodani S PMID: 33712520 PMCID: PMC7958585 DOI: 10.1136/jim-2020-001641 Abstract Studies reported to date suggest that men with COVID-19 have more severe disease and worse outcomes when compared with women. The explanation for this finding is not entirely clear. The goal of this study was to compare clinical characteristics, [...]